Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion

• DOI: 10.3389/fonc.2024.1370901
• Publication Date: 2024-04-16T05:01:30Z
• Authors: Su-Su Dong; Wen Dong; Ya-Fen Tan; Qiang Xiao; Tian-Li Wang
• Keywords: 0301 basic medicine; crizotinib; 03 medical and health sciences; MET fusion; Oncology; acquired resistance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; non-small cell lung cancer; RC254-282; gene mutations

Background The c-met proto-oncogene ( MET ) serves as a significant primary oncogenic driver in non-small cell lung cancer (NSCLC) and has the potential to fuse with other genes, such KIF5B , although it occurs infrequently. Only limited number of reported cases have examined clinical efficacy crizotinib patients KIF5B-MET gene fusion, no known data regarding acquired resistance its mechanisms. In this report, we present progression female patient diagnosed NSCLC harboring fusion. Case description initially exhibited partial response first-line treatment, albeit for short duration efficacy. Subsequent disease revealed emergence secondary mutation, specifically Y1230H, leading crizotinib. Conclusion reporting case is imperative informing practice, given uncommon occurrence displaying responsiveness tyrosine kinase inhibitor therapy, well Y1230H alteration mechanism.